SG11201610243YA - Treatment of severe hypertriglyceridemia - Google Patents

Treatment of severe hypertriglyceridemia

Info

Publication number
SG11201610243YA
SG11201610243YA SG11201610243YA SG11201610243YA SG11201610243YA SG 11201610243Y A SG11201610243Y A SG 11201610243YA SG 11201610243Y A SG11201610243Y A SG 11201610243YA SG 11201610243Y A SG11201610243Y A SG 11201610243YA SG 11201610243Y A SG11201610243Y A SG 11201610243YA
Authority
SG
Singapore
Prior art keywords
treatment
severe hypertriglyceridemia
hypertriglyceridemia
severe
Prior art date
Application number
SG11201610243YA
Other languages
English (en)
Inventor
Pol Boudes
Yun-Jung Choi
Robert L Martin
Charles A Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of SG11201610243YA publication Critical patent/SG11201610243YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
SG11201610243YA 2014-06-26 2015-06-25 Treatment of severe hypertriglyceridemia SG11201610243YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462017444P 2014-06-26 2014-06-26
PCT/US2015/037596 WO2015200580A1 (en) 2014-06-26 2015-06-25 Treatment of severe hypertriglyceridemia

Publications (1)

Publication Number Publication Date
SG11201610243YA true SG11201610243YA (en) 2017-01-27

Family

ID=53511030

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201610243YA SG11201610243YA (en) 2014-06-26 2015-06-25 Treatment of severe hypertriglyceridemia

Country Status (16)

Country Link
US (1) US20150374649A1 (enExample)
EP (1) EP3160458A1 (enExample)
JP (1) JP2017519028A (enExample)
KR (1) KR20170020514A (enExample)
CN (1) CN106470675A (enExample)
AU (1) AU2015279905A1 (enExample)
BR (1) BR112016028918A2 (enExample)
CA (1) CA2951280A1 (enExample)
CL (1) CL2016003290A1 (enExample)
EA (1) EA201790091A1 (enExample)
HK (1) HK1231380A1 (enExample)
IL (1) IL249757A0 (enExample)
MX (1) MX2016017081A (enExample)
PH (1) PH12016502415A1 (enExample)
SG (1) SG11201610243YA (enExample)
WO (1) WO2015200580A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN106163508A (zh) 2014-04-11 2016-11-23 西玛贝医药公司 Nafld和nash的治疗
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN111741753A (zh) * 2017-12-21 2020-10-02 兴和株式会社 治疗高甘油三酯血症的方法
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1667964T3 (pl) 2003-09-19 2010-01-29 Janssen Pharmaceutica Nv Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i analogi
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
KR20130073884A (ko) * 2010-03-30 2013-07-03 노파르티스 아게 Ｄｇａｔ1 억제제의 용도

Also Published As

Publication number Publication date
JP2017519028A (ja) 2017-07-13
PH12016502415A1 (en) 2017-02-27
EA201790091A1 (ru) 2017-07-31
CL2016003290A1 (es) 2017-09-08
WO2015200580A1 (en) 2015-12-30
MX2016017081A (es) 2017-05-01
EP3160458A1 (en) 2017-05-03
IL249757A0 (en) 2017-02-28
BR112016028918A2 (pt) 2017-08-22
HK1231380A1 (zh) 2017-12-22
CN106470675A (zh) 2017-03-01
AU2015279905A1 (en) 2017-02-02
CA2951280A1 (en) 2015-12-30
US20150374649A1 (en) 2015-12-31
KR20170020514A (ko) 2017-02-22

Similar Documents

Publication Publication Date Title
IL259110A (en) Treatment of osteoarthritis (osteoarthritis)
IL252839A0 (en) Treatment of boils
GB201701673D0 (en) Methods of well treatment
PL3851537T3 (pl) Leczenie hiperbilirubinemii
SG11201609265RA (en) Characterizing states of subject
IL285003A (en) Treatment of episode disorders
SG11201609652RA (en) Treatment of polybacterials infections
GB201410116D0 (en) Method of treatment
SG11201610243YA (en) Treatment of severe hypertriglyceridemia
IL246880A0 (en) Tumor treatment
IL253028A0 (en) treatment method
GB201416832D0 (en) Methods of treatment
GB201408297D0 (en) Treatment of cancer
IL249130A0 (en) Preparation of piperidine-4-carbthioamide
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201411027D0 (en) Treatment
GB201402298D0 (en) Processing of microalgae
GB201512139D0 (en) Methods of treatment
GB201417456D0 (en) Treatment of cancer
GB201407806D0 (en) Treatment of fibrosis
GB201412411D0 (en) Treatment
ZA201504639B (en) Treatment of water
GB201409362D0 (en) Treatment of cancer
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer